StemCell Institute Inc.
7096.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.47 | 1.10 | 2.80 | 1.44 |
| FCF Yield | -0.07% | 0.69% | 0.15% | 1.30% |
| EV / EBITDA | 16.13 | 30.77 | 55.78 | 54.36 |
| Quality | ||||
| ROIC | 8.78% | 10.46% | 8.87% | 6.60% |
| Gross Margin | 63.16% | 63.51% | 63.88% | 62.36% |
| Cash Conversion Ratio | 1.21 | 1.08 | 0.50 | 2.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.61% | 11.67% | 14.06% | 2.06% |
| Free Cash Flow Growth | -107.60% | 234.35% | -84.98% | 261.13% |
| Safety | ||||
| Net Debt / EBITDA | -3.86 | -5.31 | -8.24 | -11.35 |
| Interest Coverage | 348.18 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 19.36 | 21.42 | 19.20 | 16.70 |
| Cash Conversion Cycle | 259.82 | 235.82 | 202.87 | 127.31 |